Brendan Smith
Stock Analyst at TD Cowen
(2.24)
# 2,735
Out of 4,963 analysts
6
Total ratings
60%
Success rate
8.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings | Maintains: Buy | $3 → $10 | $12.78 | -21.75% | 1 | Sep 20, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $59 → $65 | $72.93 | -10.87% | 2 | Aug 7, 2024 | |
| NVAX Novavax | Maintains: Hold | $5 → $10 | $7.50 | +33.33% | 1 | May 13, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | n/a | $21.18 | - | 1 | Jul 21, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | n/a | $15.55 | - | 1 | Dec 5, 2022 |
Ginkgo Bioworks Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $3 → $10
Current: $12.78
Upside: -21.75%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $59 → $65
Current: $72.93
Upside: -10.87%
Novavax
May 13, 2024
Maintains: Hold
Price Target: $5 → $10
Current: $7.50
Upside: +33.33%
Arrowhead Pharmaceuticals
Jul 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $21.18
Upside: -
Denali Therapeutics
Dec 5, 2022
Initiates: Outperform
Price Target: n/a
Current: $15.55
Upside: -